Leadership in AD/ADRD Drug Discovery

总结 此R35领导力应用程序与NIH阿尔茨海默氏症的目标/里程碑的里程碑6D相关 疾病和阿尔茨海默病相关痴呆（AD/ADRD）峰会-“启动药物发现工作， 开发新的治疗药物。”我们在这个应用程序中的首要目标是支持PI的基础设施 正在斯克里普斯研究中心为AD/ADRD药物发现而聚集，该研究将在获奖后继续进行。 结束了我们的主要计划里程碑旨在激励计划建设和创建团队建设， AD/ADRD药物发现利用Scripps Research的大量机构资源， Calibr药物发现中心我们还在建设全国一流的研究生院之一 通过我们的指导，使用Scripps的#1/#2排名化学系的药物发现计划- 最大的生物化学系作为可行性的证明，目前FDA批准的六种药物中， AD，三个是由PI，利普顿博士的实验室开发的。通过R35领导力应用程序，Lipton博士 将指导其他人开发AD/ADRD相关药物，用于改善疾病的新靶点， 疗法具体来说，利普顿博士将担任新的研究者和早期阶段的研究导师 AD/ADRD药物发现的研究者（NI/ESI）。到目前为止，几乎所有的AD/ADRD治疗方法都在 人类临床试验迄今未能显示对AD/ADRD的疾病改善作用。例如，缺乏 迄今为止，在以Aβ为中心的治疗方法的临床试验中， 开发有效的AD治疗剂。为了克服这些重大的知识差距， 治疗，AD/ADRD研究人员运作和执行的模型和策略的改进 需要发生。应对这一挑战的一个解决方案是将最好的基础科学家与神经科学培训结合起来， 结构生物学，生物信息学和计算生物学，在制药领域拥有同样的专家团队， 在高通量筛选、检测开发、药物化学、化学生物学和 药理学有一个集体和和谐的团队沿着与初级教师的重大指导工作 (NI/ESI），主要研究者Lipton博士已经发起了三项主要工作来解决这一未满足的医疗需求， 在当前R35领导奖申请的主持下进行： ·在背景下研究、鉴定和表征潜在的AD/ADRD治疗靶点 AD/ADRD的中枢病理生理过程。 ·执行药物发现活动，以开发研究性新药（IND）临床候选药物 迭代地进行目标阐明工作，同时建立在Scripps药物发现基础设施上， 完成这个。 ·继续指导初级教师，围绕化学生物学建立世界一流的研究生院 在Scripps的AD/ADRD药物设计（目前被美国生物化学新闻排名第2）。

SUMMARY This R35 leadership application is relevant to Milestone 6D of the goals/milestones of the NIH Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) Summits—“Initiate drug discovery efforts to develop novel therapeutic agents.” Our overriding goal in this application is to support the infrastructure the PI is assembling for AD/ADRD drug discovery at Scripps Research, which will continue well after the award is over. Our major planned milestone is aimed to INSPIRE program building and create team building for AD/ADRD Drug Discovery using the very considerable institutional resources at Scripps Research and its Calibr Drug Discovery Center. We are also building one of the nation’s top-ranked Graduate School programs in drug discovery via our mentoring using the faculty of Scripps’ #1/#2-ranked chemistry- biochemistry departments in the world. As proof of feasibility, of the six currently FDA-approved medicines for AD, three were developed out of the PI, Dr. Lipton’s laboratory. Via this R35 Leadership Application, Dr. Lipton will mentor others to develop AD/ADRD-related drugs acting at novel targets toward disease-modifying therapy. Specifically, Dr. Lipton will serve as research mentor for New Investigators and Early Stage Investigators (NI/ESI) in AD/ADRD drug discovery. To date, virtually all AD/ADRD therapeutics evaluated in human clinical trials have so far failed to show disease-modifying effects for AD/ADRD. For example, the lack of significant efficacy in clinical trials with Aβ-centered therapeutics to date demands a new paradigm for development of effective AD therapeutics. To overcome these significant gaps in knowledge and to advance therapies, improvements in the models and strategies by which AD/ADRD researchers function and execute need to occur. One solution to this challenge is to unite the best basic scientists with training in neuroscience, structural biology, bioinformatics and computational biology, with equally expert teams in the pharmaceutical industry trained in high-throughput screening, assay development, medicinal chemistry, chemical biology and pharmacology. With a collective and harmonized team along with significant mentoring efforts for junior faculty (NI/ESI), the PI, Dr. Lipton, has initiated three major efforts to address this unmet medical need, which will be carried out under the auspices of the current R35 Leadership Award application: · Investigation, identification and characterization of potential AD/ADRD therapeutic targets in the context of the central pathophysiological processes in AD/ADRD. · Execution of drug discovery campaigns to develop investigational new drug (IND) clinical candidates iteratively with the target elucidation efforts, while building upon Scripps drug discovery infrastructure to accomplish this. · Continue to mentor junior faculty and build a world-class graduate school around the chemical biology of drug design for AD/ADRD at Scripps (currently ranked #2 by US News for Biochemistry).